RecruitingPhase 2Phase 3NCT07204275
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
Sponsor
Vertex Pharmaceuticals Incorporated
Enrollment
176 participants
Start Date
Sep 30, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria1
- • Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility
Exclusion Criteria1
- • Hypersensitivity to investigational medicinal product or to any of its excipients
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPovetacicept
Solution for Subcutaneous Injection.
DRUGTacrolimus
Capsules for Oral Administration.
Locations(73)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07204275
Related Trials
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT0696280085 locations
Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT0646613550 locations
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
NCT0655726516 locations
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT0715778739 locations
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT0709684333 locations